Multicenter phase II trial of etoposide in refractory small cell lung cancer

B. F. Issell, Lawrence Einhorn, R. L. Comis, R. D. Lawson, L. H. Baker, H. A. Harvey, V. A. Lanzotti, G. L. Wampler, J. R. Daniels, P. N. Anderson

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The results indicate that etoposide as a single agent has only minimal activity in patients who have failed prior intensive chemotherapy and confirm the reports of other, recent, smaller studies in patients who had failed similar initial therapy. It is not uncommon for large multi-institutional studies to be less positive than studies in smaller numbers of patients at single institutions.

Original languageEnglish (US)
Pages (from-to)127-128
Number of pages2
JournalCancer Treatment Reports
Volume69
Issue number1
StatePublished - 1985
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Etoposide
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Issell, B. F., Einhorn, L., Comis, R. L., Lawson, R. D., Baker, L. H., Harvey, H. A., ... Anderson, P. N. (1985). Multicenter phase II trial of etoposide in refractory small cell lung cancer. Cancer Treatment Reports, 69(1), 127-128.

Multicenter phase II trial of etoposide in refractory small cell lung cancer. / Issell, B. F.; Einhorn, Lawrence; Comis, R. L.; Lawson, R. D.; Baker, L. H.; Harvey, H. A.; Lanzotti, V. A.; Wampler, G. L.; Daniels, J. R.; Anderson, P. N.

In: Cancer Treatment Reports, Vol. 69, No. 1, 1985, p. 127-128.

Research output: Contribution to journalArticle

Issell, BF, Einhorn, L, Comis, RL, Lawson, RD, Baker, LH, Harvey, HA, Lanzotti, VA, Wampler, GL, Daniels, JR & Anderson, PN 1985, 'Multicenter phase II trial of etoposide in refractory small cell lung cancer', Cancer Treatment Reports, vol. 69, no. 1, pp. 127-128.
Issell BF, Einhorn L, Comis RL, Lawson RD, Baker LH, Harvey HA et al. Multicenter phase II trial of etoposide in refractory small cell lung cancer. Cancer Treatment Reports. 1985;69(1):127-128.
Issell, B. F. ; Einhorn, Lawrence ; Comis, R. L. ; Lawson, R. D. ; Baker, L. H. ; Harvey, H. A. ; Lanzotti, V. A. ; Wampler, G. L. ; Daniels, J. R. ; Anderson, P. N. / Multicenter phase II trial of etoposide in refractory small cell lung cancer. In: Cancer Treatment Reports. 1985 ; Vol. 69, No. 1. pp. 127-128.
@article{56a60d7e1f9a42f4b91c5002706b8ac9,
title = "Multicenter phase II trial of etoposide in refractory small cell lung cancer",
abstract = "The results indicate that etoposide as a single agent has only minimal activity in patients who have failed prior intensive chemotherapy and confirm the reports of other, recent, smaller studies in patients who had failed similar initial therapy. It is not uncommon for large multi-institutional studies to be less positive than studies in smaller numbers of patients at single institutions.",
author = "Issell, {B. F.} and Lawrence Einhorn and Comis, {R. L.} and Lawson, {R. D.} and Baker, {L. H.} and Harvey, {H. A.} and Lanzotti, {V. A.} and Wampler, {G. L.} and Daniels, {J. R.} and Anderson, {P. N.}",
year = "1985",
language = "English (US)",
volume = "69",
pages = "127--128",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Multicenter phase II trial of etoposide in refractory small cell lung cancer

AU - Issell, B. F.

AU - Einhorn, Lawrence

AU - Comis, R. L.

AU - Lawson, R. D.

AU - Baker, L. H.

AU - Harvey, H. A.

AU - Lanzotti, V. A.

AU - Wampler, G. L.

AU - Daniels, J. R.

AU - Anderson, P. N.

PY - 1985

Y1 - 1985

N2 - The results indicate that etoposide as a single agent has only minimal activity in patients who have failed prior intensive chemotherapy and confirm the reports of other, recent, smaller studies in patients who had failed similar initial therapy. It is not uncommon for large multi-institutional studies to be less positive than studies in smaller numbers of patients at single institutions.

AB - The results indicate that etoposide as a single agent has only minimal activity in patients who have failed prior intensive chemotherapy and confirm the reports of other, recent, smaller studies in patients who had failed similar initial therapy. It is not uncommon for large multi-institutional studies to be less positive than studies in smaller numbers of patients at single institutions.

UR - http://www.scopus.com/inward/record.url?scp=0022007273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022007273&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 127

EP - 128

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 1

ER -